Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179396 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
A Phase 1 study, sponsored by pharmaand.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04179396 is a Phase 1 study that has completed, run by pharmaand. The registered enrollment target is 8 participants.
The verdict
NCT04179396, a Phase 1 study, has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2023-01-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04179396
The ClinicalTrials.gov registry entry for NCT04179396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Enzalutamide is the first listed.
NCT04179396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04179396 about?
NCT04179396 is a clinical study titled "Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)". Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
What is the current status of trial NCT04179396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-12-05. Estimated completion is 2023-01-18.
What interventions are being tested in trial NCT04179396?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT04179396?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.